Bills › 90th General Assembly
HSB 536
Topics:Business & economy
Where it is now
- Done: IntroducedJanuary 9, 2024
- Done: SubcommitteeJanuary 9, 2024
- Done: House committeeJanuary 18, 2024
- Skipped: Passes the HouseContinued as HF 2099
- Next: Senate committee
- Next: Passes the Senate
- Next: To the Governor
- Next: Signed into law
Became HF 2099 → Its progress continues under the new number. Go to HF 2099 What’s a funnel?
What’s in it
This bill relates to the regulation of pharmacy benefits managers (PBMs). Under current law, a PBM owes a duty of good faith and fair dealing to third-party payors. The bill expands that duty to pharmacies. The bill prohibits retaliation by a PBM against a pharmacy based on the pharmacy’s exercise of any right or remedy, or on the pharmacy’s cooperation with the commissioner. Prohibited retaliation includes terminating or refusing to renew a contract with a pharmacy, subjecting a pharmacy to increased audits, or withholding or failing to promptly pay the pharmacy any money owed by the PBM.
Read the full explanation
Current law prohibits a PBM from assessing, charging, or collecting any form of renumeration that passes from a pharmacist in a pharmacy network to the PBM. Under the bill, a PBM is prohibited from assessing, charging, or collecting any form of renumeration that passes from any pharmacist, regardless of whether the pharmacist is in a pharmacy network. Under current law, for each maximum allowable cost list that a PBM uses, a PBM shall update the maximum allowable cost list within seven days from the date of an increase of percent or more in the pharmacy acquisition cost of a prescription drug on the list. _____ list that a PBM uses, a PBM shall update the maximum allowable cost list within seven days from the date of an increase of percent or more in the national average drug acquisition cost of a prescription drug on the list. The bill requires that the annual report provided by a PBM to the commissioner of insurance regarding prescription drug benefits provided to covered persons of each third-party payor with whom the PBM has contracted during the prior calendar year be in a format that does not publicly disclose the identity of a specific third-party payor, the price charged by a specific pharmaceutical manufacturer for prescription drugs, or the amount of rebates provided for prescription drugs.
House subcommittee
Named January 9, 2024. On January 16, 2024 it recommended passage. Vote Total: 3-0.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Iowa Code it changes
Creates§510B.4A
Lobbying
6 for · 0 against · 27 undecided · Who →
Family tree
Study bill
90th General Assembly